Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

878.29 +12.32 (+1.42%)
Official Closing Price Updated: 7:00 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,088,411
Open 870.00
Bid (Size) 873.52 (1)
Ask (Size) 876.79 (1)
Prev. Close 865.97
Today's Range 864.08 - 887.72
52wk Range 446.56 - 966.10
Shares Outstanding N/A
Dividend Yield 0.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. 
Via The Motley Fool

Performance

YTD
+48.31%
+48.31%
1 Month
-1.33%
-1.33%
3 Month
+17.78%
+17.78%
6 Month
+39.48%
+39.48%
1 Year
+91.22%
+91.22%

More News

Read More
Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
Via InvestorPlace
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Via Benzinga
Will Eli Lilly Do a Stock Split in 2024?
Via The Motley Fool
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Via The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Via The Motley Fool
SPDR ETF Report For Friday, July 19
Via Talk Markets
Topics ETFs
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Via Benzinga
Is Viking Therapeutics a Millionaire-Maker?
Via The Motley Fool
Here's How Saving Just $10 Per Day for 30 Years Can Create a $1 Million Portfolio
Via The Motley Fool
Nvidia Recently Completed a 10-for-1 Stock Split: Here Are the 3 Likeliest Candidates to Become Wall Street's Next Stock-Split Stocks
Via The Motley Fool
Palantir, Netflix, Domino's Pizza, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Eli Lilly And Company Shares Thursday?
Via Benzinga
Teva's Migraine Treatment Found Effective For Children As Young As 6
Via Benzinga
3 High-Flying Stocks That Show No Signs of Slowing Down
Via InvestorPlace
3 Reliable Blue-Chip Stocks to Buy, Hold and Never Let Go
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2023 Diversified Communications. All rights reserved.